JP2001522891A - 睡眠時無呼吸を治療するためのミルタザピンの使用 - Google Patents
睡眠時無呼吸を治療するためのミルタザピンの使用Info
- Publication number
- JP2001522891A JP2001522891A JP2000520789A JP2000520789A JP2001522891A JP 2001522891 A JP2001522891 A JP 2001522891A JP 2000520789 A JP2000520789 A JP 2000520789A JP 2000520789 A JP2000520789 A JP 2000520789A JP 2001522891 A JP2001522891 A JP 2001522891A
- Authority
- JP
- Japan
- Prior art keywords
- sleep apnea
- mirtazapine
- apnea
- sleep
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000002859 sleep apnea Diseases 0.000 title claims abstract description 20
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229960001785 mirtazapine Drugs 0.000 title claims abstract description 15
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims abstract description 10
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 abstract description 16
- 230000000694 effects Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 230000007958 sleep Effects 0.000 description 8
- 208000008784 apnea Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 230000000414 obstructive effect Effects 0.000 description 4
- 208000001797 obstructive sleep apnea Diseases 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- 208000003417 Central Sleep Apnea Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000020020 complex sleep apnea Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 201000006646 mixed sleep apnea Diseases 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 229960004038 fluvoxamine Drugs 0.000 description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 1
- 229950003930 femoxetine Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- ZHFIAFNZGWCLHU-YPMHNXCESA-N ifoxetine Chemical compound CC1=CC=CC(O[C@@H]2[C@@H](CNCC2)O)=C1C ZHFIAFNZGWCLHU-YPMHNXCESA-N 0.000 description 1
- 229950006314 ifoxetine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229950004138 litoxetine Drugs 0.000 description 1
- MJJDYOLPMGIWND-UHFFFAOYSA-N litoxetine Chemical compound C=1C=C2C=CC=CC2=CC=1COC1CCNCC1 MJJDYOLPMGIWND-UHFFFAOYSA-N 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 210000003105 phrenic nerve Anatomy 0.000 description 1
- 229920005596 polymer binder Polymers 0.000 description 1
- 239000002491 polymer binding agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 229940066293 respiratory stimulants Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97203548 | 1997-11-14 | ||
EP97203548.9 | 1997-11-14 | ||
PCT/EP1998/007330 WO1999025356A1 (en) | 1997-11-14 | 1998-11-13 | Use of mirtazapine for treating sleep apneas |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001522891A true JP2001522891A (ja) | 2001-11-20 |
Family
ID=8228923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000520789A Pending JP2001522891A (ja) | 1997-11-14 | 1998-11-13 | 睡眠時無呼吸を治療するためのミルタザピンの使用 |
Country Status (21)
Country | Link |
---|---|
US (1) | US6303595B1 (de) |
EP (1) | EP1030667B1 (de) |
JP (1) | JP2001522891A (de) |
KR (1) | KR20010032009A (de) |
CN (1) | CN1154495C (de) |
AT (1) | ATE289816T1 (de) |
AU (1) | AU737590B2 (de) |
BR (1) | BR9815098A (de) |
CA (1) | CA2309744A1 (de) |
CZ (1) | CZ296282B6 (de) |
DE (1) | DE69829202T2 (de) |
DK (1) | DK1030667T3 (de) |
ES (1) | ES2238781T3 (de) |
HK (1) | HK1029932A1 (de) |
HU (1) | HUP0100080A3 (de) |
IL (2) | IL135825A0 (de) |
NO (1) | NO20002218L (de) |
PL (1) | PL192272B1 (de) |
PT (1) | PT1030667E (de) |
TR (1) | TR200001293T2 (de) |
WO (1) | WO1999025356A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060241164A1 (en) * | 1998-02-27 | 2006-10-26 | The Board Of Trustees Of The University Of Illinoi | Pharmacological treatment for sleep apnea |
CA2321900C (en) | 1998-02-27 | 2011-07-19 | The Board Of Trustees Of The University Of Illinois | Agents with serotonin-related activity for the treatment for sleep apnea |
US7160898B2 (en) * | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
CA2396209C (en) * | 2000-02-11 | 2009-09-01 | Akzo Nobel N.V. | The use of mirtazapine for the treatment of sleep disorders |
US20020183306A1 (en) * | 2001-05-30 | 2002-12-05 | Pfizer Inc. | Combination treatment for sleep disorders including sleep apnea |
UA83666C2 (ru) | 2003-07-10 | 2008-08-11 | Н.В. Органон | Способ получения энантиомерно чистого миртазапина |
US7838029B1 (en) | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
WO2005023767A2 (en) | 2003-09-10 | 2005-03-17 | Brentwood Equities Ltd. | Diastereomers of 4-aryloxy-3-hydroxypiperidines |
WO2006023702A2 (en) * | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders with setiptiline |
WO2006055854A2 (en) * | 2004-11-17 | 2006-05-26 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtazapine treatment |
US8512751B2 (en) | 2004-12-20 | 2013-08-20 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
JP5635905B2 (ja) | 2007-04-11 | 2014-12-03 | メルク・シャープ・エンド・ドーム・ベー・フェー | ミルタザピンの調製方法 |
WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
WO2013188806A1 (en) * | 2012-06-14 | 2013-12-19 | The Regents Of The University Of Michigan | Sleep apnea treatment |
PL3261645T3 (pl) | 2015-02-27 | 2021-12-06 | Dechra Limited | Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
EP0517984A1 (de) | 1991-06-11 | 1992-12-16 | Merrell Dow Pharmaceuticals Inc. | Amidanaloge-Derivate von methanoverbrückten Chinolizinen |
EP0866711B1 (de) * | 1995-10-24 | 2006-07-26 | Grünenthal GmbH | Montirelin zur verhinderung der schlafapnoe |
SE9504537D0 (sv) * | 1995-12-19 | 1995-12-19 | Jan Hedner | Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet |
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
-
1998
- 1998-11-13 BR BR9815098-7A patent/BR9815098A/pt not_active Application Discontinuation
- 1998-11-13 JP JP2000520789A patent/JP2001522891A/ja active Pending
- 1998-11-13 EP EP98962348A patent/EP1030667B1/de not_active Expired - Lifetime
- 1998-11-13 TR TR2000/01293T patent/TR200001293T2/xx unknown
- 1998-11-13 PT PT98962348T patent/PT1030667E/pt unknown
- 1998-11-13 IL IL13582598A patent/IL135825A0/xx active IP Right Grant
- 1998-11-13 HU HU0100080A patent/HUP0100080A3/hu unknown
- 1998-11-13 ES ES98962348T patent/ES2238781T3/es not_active Expired - Lifetime
- 1998-11-13 CA CA002309744A patent/CA2309744A1/en not_active Abandoned
- 1998-11-13 CN CNB988111349A patent/CN1154495C/zh not_active Expired - Fee Related
- 1998-11-13 CZ CZ20001751A patent/CZ296282B6/cs not_active IP Right Cessation
- 1998-11-13 PL PL340467A patent/PL192272B1/pl not_active IP Right Cessation
- 1998-11-13 US US09/554,143 patent/US6303595B1/en not_active Expired - Fee Related
- 1998-11-13 KR KR1020007005121A patent/KR20010032009A/ko not_active Application Discontinuation
- 1998-11-13 AU AU17548/99A patent/AU737590B2/en not_active Ceased
- 1998-11-13 DK DK98962348T patent/DK1030667T3/da active
- 1998-11-13 DE DE69829202T patent/DE69829202T2/de not_active Expired - Fee Related
- 1998-11-13 AT AT98962348T patent/ATE289816T1/de not_active IP Right Cessation
- 1998-11-13 WO PCT/EP1998/007330 patent/WO1999025356A1/en not_active Application Discontinuation
-
2000
- 2000-04-25 IL IL135825A patent/IL135825A/en not_active IP Right Cessation
- 2000-04-28 NO NO20002218A patent/NO20002218L/no not_active Application Discontinuation
-
2001
- 2001-02-05 HK HK01100800A patent/HK1029932A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1278731A (zh) | 2001-01-03 |
CN1154495C (zh) | 2004-06-23 |
KR20010032009A (ko) | 2001-04-16 |
PL192272B1 (pl) | 2006-09-29 |
DE69829202D1 (de) | 2005-04-07 |
CZ20001751A3 (cs) | 2000-10-11 |
HUP0100080A2 (hu) | 2001-08-28 |
AU737590B2 (en) | 2001-08-23 |
ATE289816T1 (de) | 2005-03-15 |
IL135825A (en) | 2006-12-31 |
CA2309744A1 (en) | 1999-05-27 |
CZ296282B6 (cs) | 2006-02-15 |
HUP0100080A3 (en) | 2002-05-28 |
EP1030667A1 (de) | 2000-08-30 |
DK1030667T3 (da) | 2005-06-20 |
ES2238781T3 (es) | 2005-09-01 |
EP1030667B1 (de) | 2005-03-02 |
TR200001293T2 (tr) | 2002-09-23 |
PT1030667E (pt) | 2005-06-30 |
WO1999025356A1 (en) | 1999-05-27 |
NO20002218L (no) | 2000-05-12 |
PL340467A1 (en) | 2001-02-12 |
AU1754899A (en) | 1999-06-07 |
IL135825A0 (en) | 2001-05-20 |
DE69829202T2 (de) | 2005-07-21 |
US6303595B1 (en) | 2001-10-16 |
NO20002218D0 (no) | 2000-04-28 |
BR9815098A (pt) | 2000-10-10 |
HK1029932A1 (en) | 2001-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001522891A (ja) | 睡眠時無呼吸を治療するためのミルタザピンの使用 | |
JP2002542287A (ja) | 医 薬 | |
WO2012166909A1 (en) | Compositions and methods for treating breathing control disorders or diseases | |
CA2295119C (en) | Use of a specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing | |
AU779696B2 (en) | Methods for treating apnea and apnea disorders using optically pure R(+)ondansetron | |
KR100681360B1 (ko) | 타액분비 촉진용 카르보스티릴 유도체 | |
JP2002541190A (ja) | 気分障害治療用医薬を製造するためのオサネタントの使用 | |
JP2008255064A (ja) | 睡眠障害予防治療剤 | |
JP2002532548A (ja) | いびきおよび解剖学的上気道の高抵抗症候群を治療するための薬剤を製造するための5ht2aおよび5ht2a/c受容体アンタゴニストの使用 | |
EP1642589A1 (de) | Mittel zur prävention/behandlung von schnarchen oder atemstörungen im schlaf | |
RU2819722C2 (ru) | Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями | |
JP2003500353A (ja) | 処置方法 | |
MXPA00004609A (en) | Use of mirtazapine for treating sleep apneas | |
WO2023177329A1 (ru) | Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями | |
MXPA01006464A (en) | Use of a 5ht2a and 5ht2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways | |
MXPA99012044A (en) | Use of a specific antagonist of 5ht2 | |
WO2007034778A1 (ja) | 睡眠障害予防治療剤 | |
JP2008303146A (ja) | 睡眠障害予防治療剤 | |
EP1435238A1 (de) | Verfahren zur Behandlung von Apnoe und Apnoe-Erkrankungen mit optisch reinem R(+)Ondansetron |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051021 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081209 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090302 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090309 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090901 |